Navigation Links
Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Date:11/28/2012

ares of Series E Preferred Stock was done in a way that was beneficial to both PBI and Ironridge; and the size of the life sciences sample preparation market.  These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's sales forces may not be successful in selling the Company's product lines because scientists may not perceive the advantages of the Company's PCT products over other sample preparation methods; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital sooner than anticipated. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond December 2012 on acceptable terms, if at all.  Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

       &#
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
2. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
3. Convenient New iHealth Blood Pressure Monitors and Body Analysis Scale Now Available for Purchase at Major Retailers and Online
4. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
5. Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food P
6. South and Central America Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multiparameter Patient Monitoring, Neonatal Monitors, Non-Invasive Blood Pressure Monitors and Others
7. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
8. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
9. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
10. Long-Term Use of Blood Pressure Medications that Promote Sun Sensitivity May Increase Risk of Lip Cancer in Non-Hispanic Whites
11. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... , July 30, 2015  Growth of the U.S. ... they bring former prescription users to the OTC market. ... forecasts robust Rx-to-OTC switch activity over the next ... along with many new brands entering the market into ... the next five years (even those with low to ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Company (NYSE:  KVa/KVb) announced today that it has entered into ... II, L.L.C. for a $20 million loan secured by assets ... loan for working capital and general operating purposes.   ... L.L.C. and U.S. Healthcare II, L.L.C., has entered into a ...
... leader in centralized expert evaluation of CNS disorders, announced ... has approved the first New Drug Application (NDA) for ... MedAvante centralized raters. Johnson and Johnson Pharmaceutical ... for the drug paliperidone palmitate, now known as Invega ...
Cached Medicine Technology:K-V Pharmaceutical Company Secures $20 Million Loan 2K-V Pharmaceutical Company Secures $20 Million Loan 3K-V Pharmaceutical Company Secures $20 Million Loan 4K-V Pharmaceutical Company Secures $20 Million Loan 5K-V Pharmaceutical Company Secures $20 Million Loan 6K-V Pharmaceutical Company Secures $20 Million Loan 7K-V Pharmaceutical Company Secures $20 Million Loan 8FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 2FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters 3
(Date:7/31/2015)... ... ... Down is a reputable source of authentic tickets for the 2015 iHeart Radio Music ... genre of music will have an act they are excited to see at this two-day ... artists will perform: Sam Smith, Coldplay, Kenny Chesney, The Who, Jason Derulo, Demi Lovato, ...
(Date:7/31/2015)... ... ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened a ... July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and Latin ... Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department of ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... is currently going on in Chicago at Grant Park. The festival will end ... of North America to Chicago for the annual Lollapalooza. This unique and unbelievably ...
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
(Date:7/31/2015)... ... , ... The 2nd annual Ride to Fight On will start and end ... The Ride to Fight On is a cycling fundraiser that benefits the West Cancer ... and The University of Tennessee Health Science Center. A health and wellness festival featuring ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... Scientists working at the Medical Research Council have identified ... pre-cancerous cells in the esophagus, a condition called Barrett,s ... these cells before they develop into esophageal cancer. These ... have important implications for patients and may help to ...
... News) -- Soccer players need to use the correct ... or redirect the ball -- to prevent possible brain injury, ... link between the sport and brain damage, Dr. Alejandro Spiotta ... are moving at high speeds when they come into contact ...
... -- A study about how wearing contact lenses affects ... Loyola University Chicago Stritch School of Medicine,s annual St. ... study is Marie Brenner, a fourth-year student at Stritch ... effects of contact lens wear on retinal nerve fiber ...
... an accepted way to simplify a complex array of symptoms ... an independent disease in itself. However, the truth is not ... at work explaining the symptoms. This is also one of ... not bring the hoped result," says Kari Tikkinen, MD, PhD, ...
... The University of Kentucky will be the first site ... the entire country participating in the first stages of a ... human adult stem cell product, on patients with acute ischemic ... stroke protocol B01-02, was recently approved by UK,s institutional review ...
... By Alan Mozes HealthDay Reporter , ... smartphone may not actually be that smart, British researchers ... study that finds an association between the increasingly popular ... levels. The reason: a relentless need to immediately ...
Cached Medicine News:Health News:Researchers use sugar to halt esophageal cancer in its tracks 2Health News:Heading Soccer Balls Could Injure Brain 2Health News:The concept of 'overactive bladder' serves better commercial rather than patient interests 2Health News:Your Smartphone May Be Stressing You Out 2Health News:Your Smartphone May Be Stressing You Out 3
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for continuous, random access operation, the Elecsys ... to large volume laboratories that want to ... the simplicity, flexibility and Stat capabilities of ... be adapted to the changing needs of ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... The SkanWasher 400 ... 96-well microplate washer with ... pumps. The individual pressure ... a very gentle wash ...
Medicine Products: